Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled
Metric Merck (MRK) Last Price (10/10/25) $86.02 marketbeat.com Market Cap $215B marketbeat.com P/E (TTM) ~13× marketbeat.com Yield 3.8% marketbeat.com 52-Week Range $73.31 – $111.58 marketbeat.com YTD Total Return -11.07% financecharts.com Q2 2025 Sales $15.8B investing.com 2024 Sales $64.2B merck.com 2024 R&D Spend $17.9B merck.com Analyst PT (avg) $104 (12-mo) marketbeat.com Consensus Rating Hold marketbeat.com Company Overview Merck & Co. (MRK, called MSD outside North America) is a global healthcare company (75,000 employees merck.com) organized in Pharmaceuticals, Vaccines and Animal Health. It focuses on oncology/immunology, infectious disease (including vaccines), cardio-metabolic, and hospital specialty medicines merck.com. Its blockbuster product KEYTRUDA® (pembrolizumab) – a PD-1 checkpoint